CA3030792A1 - Procede et systeme de pharmacogenomique microbienne - Google Patents
Procede et systeme de pharmacogenomique microbienne Download PDFInfo
- Publication number
- CA3030792A1 CA3030792A1 CA3030792A CA3030792A CA3030792A1 CA 3030792 A1 CA3030792 A1 CA 3030792A1 CA 3030792 A CA3030792 A CA 3030792A CA 3030792 A CA3030792 A CA 3030792A CA 3030792 A1 CA3030792 A1 CA 3030792A1
- Authority
- CA
- Canada
- Prior art keywords
- microbiome
- antibiotics
- features
- pharmacogenomics
- user
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 155
- 230000002974 pharmacogenomic effect Effects 0.000 title claims abstract description 139
- 230000000813 microbial effect Effects 0.000 title claims abstract description 30
- 244000005700 microbiome Species 0.000 claims abstract description 318
- 238000012512 characterization method Methods 0.000 claims abstract description 155
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 143
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 129
- 238000011282 treatment Methods 0.000 claims abstract description 77
- 239000012472 biological sample Substances 0.000 claims abstract description 61
- 239000012620 biological material Substances 0.000 claims abstract description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 148
- 230000003115 biocidal effect Effects 0.000 claims description 70
- 239000000203 mixture Substances 0.000 claims description 67
- 238000012545 processing Methods 0.000 claims description 42
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 150000007523 nucleic acids Chemical class 0.000 claims description 23
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 21
- 230000003321 amplification Effects 0.000 claims description 20
- 230000001737 promoting effect Effects 0.000 claims description 19
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 230000035772 mutation Effects 0.000 claims description 15
- 238000009258 post-therapy Methods 0.000 claims description 11
- 206010018612 Gonorrhoea Diseases 0.000 claims description 8
- 208000019802 Sexually transmitted disease Diseases 0.000 claims description 8
- 208000001786 gonorrhea Diseases 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 7
- 238000003066 decision tree Methods 0.000 claims description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 6
- 238000007481 next generation sequencing Methods 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 208000019206 urinary tract infection Diseases 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 108700028369 Alleles Proteins 0.000 claims description 3
- 229930186147 Cephalosporin Natural products 0.000 claims description 3
- 229940124587 cephalosporin Drugs 0.000 claims description 3
- 150000001780 cephalosporins Chemical class 0.000 claims description 3
- 238000012217 deletion Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- 101150070420 gyrA gene Proteins 0.000 claims description 3
- 101150110811 parC gene Proteins 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 230000008707 rearrangement Effects 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 230000005945 translocation Effects 0.000 claims description 3
- 108020004705 Codon Proteins 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 101150038610 penA gene Proteins 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 239000000523 sample Substances 0.000 abstract description 26
- 238000012163 sequencing technique Methods 0.000 abstract description 26
- 230000008569 process Effects 0.000 description 53
- 230000006870 function Effects 0.000 description 30
- 238000005516 engineering process Methods 0.000 description 20
- 230000002068 genetic effect Effects 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000002596 correlated effect Effects 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 239000006041 probiotic Substances 0.000 description 9
- 235000018291 probiotics Nutrition 0.000 description 9
- 238000013459 approach Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 230000000529 probiotic effect Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 230000001747 exhibiting effect Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 244000005702 human microbiome Species 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000013500 data storage Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 230000036449 good health Effects 0.000 description 3
- -1 locus Proteins 0.000 description 3
- 238000011338 personalized therapy Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- 238000007397 LAMP assay Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 102000008579 Transposases Human genes 0.000 description 2
- 108010020764 Transposases Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000007637 random forest analysis Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- OJHZNMVJJKMFGX-RNWHKREASA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.O=C([C@@H]1O2)CC[C@H]3[C@]4([H])N(C)CC[C@]13C1=C2C(OC)=CC=C1C4 OJHZNMVJJKMFGX-RNWHKREASA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 208000035478 Interatrial communication Diseases 0.000 description 1
- 238000001276 Kolmogorov–Smirnov test Methods 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 208000006353 Ureterocele Diseases 0.000 description 1
- 206010046477 Urethral syndrome Diseases 0.000 description 1
- 208000037009 Vaginitis bacterial Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 238000001790 Welch's t-test Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 208000013914 atrial heart septal defect Diseases 0.000 description 1
- 206010003664 atrial septal defect Diseases 0.000 description 1
- 208000025255 bacterial arthritis Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000009226 cognitive therapy Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010205 computational analysis Methods 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000007849 hot-start PCR Methods 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940041028 lincosamides Drugs 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003121 nonmonotonic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 229940041153 polymyxins Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 1
- 229940081192 rifamycins Drugs 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000002922 simulated annealing Methods 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000000551 statistical hypothesis test Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000010119 systemic immune function Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical class C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 238000007862 touchdown PCR Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/746—Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/7465—Arrangements for interactive communication between patient and care services, e.g. by using a telephone network
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/13—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Data Mining & Analysis (AREA)
- Nursing (AREA)
- Physiology (AREA)
- Databases & Information Systems (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Bioethics (AREA)
Abstract
Des modes de réalisation d'un procédé et d'un système pour la pharmacogénomique microbienne peuvent comprendre : un système de manipulation d'échantillons opérationnel pour collecter des conteneurs comprenant des échantillons biologiques provenant d'un ensemble d'utilisateurs, le système de manipulation comprenant un système de séquençage opérationnel pour déterminer des séquences de micro-organismes à partir des échantillons biologiques ; un système de caractérisation de microbiome opérationnel pour : déterminer des données de pharmacogénomique de microbiome sur la base des séquences de micro-organisme, collecter des données supplémentaires associées à l'état associé aux antibiotiques pour l'ensemble d'utilisateurs, et transformer les données et caractéristiques supplémentaires extraites des données de pharmacogénomique du microbiome dans un modèle de caractérisation associé à l'état associé aux antibiotiques ; et un système de traitement opérationnel pour favoriser un traitement de l'utilisateur pour l'état associé aux antibiotiques sur la base de la caractérisation de matériau biologique d'utilisateur avec le modèle de caractérisation en relation avec l'état associé aux antibiotiques.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662361943P | 2016-07-13 | 2016-07-13 | |
| US62/361,943 | 2016-07-13 | ||
| US15/606,743 | 2017-05-26 | ||
| US15/606,743 US10803991B2 (en) | 2014-10-21 | 2017-05-26 | Method and system for microbiome-derived diagnostics and therapeutics |
| PCT/US2017/042015 WO2018013865A1 (fr) | 2016-07-13 | 2017-07-13 | Procédé et système de pharmacogénomique microbienne |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3030792A1 true CA3030792A1 (fr) | 2018-01-18 |
Family
ID=60953350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3030792A Pending CA3030792A1 (fr) | 2016-07-13 | 2017-07-13 | Procede et systeme de pharmacogenomique microbienne |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3484348A4 (fr) |
| JP (2) | JP2019521706A (fr) |
| KR (1) | KR102397683B1 (fr) |
| CN (1) | CN109475305B (fr) |
| AU (1) | AU2017295861A1 (fr) |
| BR (1) | BR112019000709A8 (fr) |
| CA (1) | CA3030792A1 (fr) |
| CO (1) | CO2019001319A2 (fr) |
| EA (1) | EA201990294A1 (fr) |
| SG (1) | SG11201900253TA (fr) |
| WO (1) | WO2018013865A1 (fr) |
| ZA (1) | ZA201900473B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3720969A4 (fr) * | 2017-12-04 | 2021-08-11 | Cybele Microbiome, Inc. | Procédés et compositions pour l'identification et la modulation des voies biochimiques du microbiome pour modifier un phénotype |
| JP2021516330A (ja) * | 2018-03-16 | 2021-07-01 | プソマーゲン， インコーポレイテッドＰｓｏｍａｇｅｎ， Ｉｎｃ． | バイオインフォマティクスアプローチに基づく、診断及び治療を含む、代謝関連状態の特徴解析のための方法及びシステム |
| JP7455757B2 (ja) * | 2018-04-13 | 2024-03-26 | フリーノーム・ホールディングス・インコーポレイテッド | 生体試料の多検体アッセイのための機械学習実装 |
| KR102346398B1 (ko) | 2020-09-01 | 2022-01-03 | 주식회사 에이아이바이오틱스 | 장내 미생물을 분석하여 평가 하는 시스템 및 평가 방법 |
| US20220367050A1 (en) * | 2021-05-12 | 2022-11-17 | Zoe Limited | Predicting gut microbiome diversity |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0889120B1 (fr) * | 1994-12-09 | 2002-04-10 | Microscience Limited | Gènes virulents dans la region VGC2 de Salmonella |
| CN1798548B (zh) * | 2003-06-02 | 2010-05-05 | 诺华疫苗和诊断公司 | 基于含吸附类毒素和含多糖抗原微粒体的免疫原性组合物 |
| CN101346626A (zh) * | 2005-10-29 | 2009-01-14 | 拜尔技术服务有限责任公司 | 用于测定具有生物来源和复杂组成的样品中一种或多种分析物的方法及其用途 |
| EP2260109A4 (fr) * | 2008-02-28 | 2011-06-08 | Univ Ohio State Res Found | Procédés et compositions à base de micro-arn permettant de diagnostiquer, de pronostiquer et de traiter des troubles liés à la prostate |
| EP2362907A4 (fr) * | 2008-11-04 | 2012-08-08 | Blood Cell Storage Inc | Extraction de l acide nucléique sur des surfaces de verre courbes |
| EP2450080A4 (fr) * | 2010-01-29 | 2013-05-29 | Ubiomed Inc | Micro-aiguille et dispositif à micro-aiguille |
| EP2547361B1 (fr) * | 2010-03-17 | 2020-10-28 | SOCPRA - Sciences et Génie, s.e.c. | Composants de vaccin bactérien provenant du staphylocoque doré et leurs utilisations |
| CN101833613A (zh) * | 2010-06-04 | 2010-09-15 | 中国科学院青岛生物能源与过程研究所 | 一种口腔微生物群落数据库及其应用 |
| US20130121968A1 (en) * | 2011-10-03 | 2013-05-16 | Atossa Genetics, Inc. | Methods of combining metagenome and the metatranscriptome in multiplex profiles |
| WO2013176774A1 (fr) * | 2012-05-25 | 2013-11-28 | Arizona Board Of Regents | Marqueurs de microbiome et thérapies pour troubles du spectre autistique |
| US20140143188A1 (en) * | 2012-11-16 | 2014-05-22 | Genformatic, Llc | Method of machine learning, employing bayesian latent class inference: combining multiple genomic feature detection algorithms to produce an integrated genomic feature set with specificity, sensitivity and accuracy |
| KR102222273B1 (ko) * | 2013-02-04 | 2021-03-08 | 세레스 테라퓨틱스, 인코포레이티드 | 조성물 및 방법 |
| CA2906135A1 (fr) * | 2013-03-15 | 2014-09-18 | Prometheon Pharma, Llc | Dispositifs, systemes et methodes d'administration transdermique de composes |
| US9466024B2 (en) * | 2013-03-15 | 2016-10-11 | Northrop Grumman Systems Corporation | Learning health systems and methods |
| JP2016530500A (ja) * | 2013-07-01 | 2016-09-29 | イクセラ，インコーポレイテッド | システム生物学的アプローチによる療法 |
| GB2535034A (en) * | 2013-07-21 | 2016-08-10 | Whole Biome Inc | Methods and systems for microbiome characterization, monitoring and treatment |
| US10920283B2 (en) * | 2013-11-01 | 2021-02-16 | Washington University | Methods to establish and restore normal gut microbiota function of subject in need thereof |
| US9663831B2 (en) * | 2014-01-25 | 2017-05-30 | uBiome, Inc. | Method and system for microbiome analysis |
| WO2016057679A1 (fr) * | 2014-10-09 | 2016-04-14 | LuminaCare Solutions Inc. | Plateforme de dosage personnalisé d'antibiotiques |
| CN107075588B (zh) * | 2014-10-21 | 2023-03-21 | 普梭梅根公司 | 用于微生物组来源的诊断和治疗的方法及系统 |
| EP3227463A4 (fr) * | 2014-12-05 | 2018-09-05 | The University of Saskatchewan | Procédés et réactifs pour détecter neisseria gonorrhoeae et ses déterminants de résistance antimicrobienne |
| CN105648060B (zh) * | 2016-01-29 | 2020-01-31 | 江汉大学 | 一种非诊断目的的人体病原微生物耐药性基因的检测方法 |
-
2017
- 2017-07-13 WO PCT/US2017/042015 patent/WO2018013865A1/fr unknown
- 2017-07-13 EP EP17828501.1A patent/EP3484348A4/fr active Pending
- 2017-07-13 BR BR112019000709A patent/BR112019000709A8/pt not_active Application Discontinuation
- 2017-07-13 CA CA3030792A patent/CA3030792A1/fr active Pending
- 2017-07-13 CN CN201780043788.6A patent/CN109475305B/zh active Active
- 2017-07-13 EA EA201990294A patent/EA201990294A1/ru unknown
- 2017-07-13 SG SG11201900253TA patent/SG11201900253TA/en unknown
- 2017-07-13 JP JP2019522621A patent/JP2019521706A/ja not_active Withdrawn
- 2017-07-13 AU AU2017295861A patent/AU2017295861A1/en not_active Abandoned
- 2017-07-13 KR KR1020197004007A patent/KR102397683B1/ko active IP Right Grant
-
2019
- 2019-01-23 ZA ZA2019/00473A patent/ZA201900473B/en unknown
- 2019-02-13 CO CONC2019/0001319A patent/CO2019001319A2/es unknown
-
2022
- 2022-03-31 JP JP2022058908A patent/JP2022079646A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190033561A (ko) | 2019-03-29 |
| ZA201900473B (en) | 2019-09-25 |
| EA201990294A1 (ru) | 2019-08-30 |
| BR112019000709A2 (pt) | 2019-05-14 |
| AU2017295861A1 (en) | 2019-01-24 |
| SG11201900253TA (en) | 2019-02-27 |
| CN109475305A (zh) | 2019-03-15 |
| JP2019521706A (ja) | 2019-08-08 |
| JP2022079646A (ja) | 2022-05-26 |
| CN109475305B (zh) | 2022-01-25 |
| BR112019000709A8 (pt) | 2023-03-21 |
| EP3484348A4 (fr) | 2021-11-24 |
| KR102397683B1 (ko) | 2022-05-13 |
| CO2019001319A2 (es) | 2019-02-19 |
| EP3484348A1 (fr) | 2019-05-22 |
| WO2018013865A1 (fr) | 2018-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10789334B2 (en) | Method and system for microbial pharmacogenomics | |
| US10246753B2 (en) | Method and system for characterizing mouth-associated conditions | |
| US10388407B2 (en) | Method and system for characterizing a headache-related condition | |
| US10415105B2 (en) | Method and system for diagnostic testing | |
| US10366793B2 (en) | Method and system for characterizing microorganism-related conditions | |
| CN109475305B (zh) | 用于微生物药物基因组学的方法和系统 | |
| CN111278995A (zh) | 表征与微生物相关联的女性生殖系统有关状况的方法和系统 | |
| AU2022202660A1 (en) | Method and system for characterization for appendix-related conditions associated with microorganisms | |
| US20180342322A1 (en) | Method and system for characterization for appendix-related conditions associated with microorganisms | |
| JP7114091B2 (ja) | パネル特徴付けのための方法およびシステム | |
| AU2016321334A1 (en) | Method and system for microbiome-derived diagnostics and therapeutics for bacterial vaginosis | |
| AU2018327227A1 (en) | Nasal-related characterization associated with the nose microbiome | |
| AU2016321328A1 (en) | Method and system for microbiome-derived diagnostics and therapeutics infectious disease and other health conditions associated with antibiotic usage | |
| EP3426794A1 (fr) | Procédé et système de caractérisation d'états pathologiques associés à la bouche | |
| WO2018112459A1 (fr) | Procédé et système destinés à la caractérisation d'états pathologiques apparentés à un microorganisme | |
| US11783914B2 (en) | Method and system for panel characterizations | |
| EP3687375A1 (fr) | Procédé et système pour caractériser une affection liée à une céphalée |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211129 |
|
| EEER | Examination request |
Effective date: 20211129 |
|
| EEER | Examination request |
Effective date: 20211129 |
|
| EEER | Examination request |
Effective date: 20211129 |
|
| EEER | Examination request |
Effective date: 20211129 |
|
| EEER | Examination request |
Effective date: 20211129 |
|
| EEER | Examination request |
Effective date: 20211129 |